Dyne therapeutics competitors
WebModerna Inc. stock outperforms competitors on strong trading day. MRNA +3.87% COMP +1.97%. MarketWatch · 2 days ago. Analyst. ... Dyne Therapeutics Inc. is a muscle disease company. The Company ... WebDyne Therapeutics Inc Working Capital Per Revenue on the trailing twelve month basis from the forth quarter 2024 to forth quarter 2024, Trends and Ranking, Fundamental Ratios - CSIMarket ... Dyne Therapeutics Inc 's Competition Performance; Dyne Therapeutics Inc 's Competitors Results; DYN's Competitors Stock Performance;
Dyne therapeutics competitors
Did you know?
WebDyne Therapeutics Inc 's competitive profile, comparisons of quarterly results to its competitors, by sales, income, profitability, market share by products and services - … WebDec 30, 2024 · Peers & Competitors. Follow $11.59 0.19 (+1.67%) 3:59 PM 12/30/22. ... Dyne Therapeutics, Inc. (DYN) key stats comparison: compare with other stocks by …
WebApr 4, 2024 · 5 brokerages have issued twelve-month target prices for Dyne Therapeutics' shares. Their DYN share price forecasts range from $18.00 to $34.00. On average, they … WebMay 16, 2024 · DYNE-101 is designed to enable targeted delivery to muscle tissue and address the genetic basis of the disease. The new data being presented during ASGCT evaluated monthly repeat doses of DYNE-101 ...
WebMar 30, 2024 · 85.5% of Dyne Therapeutics shares are held by institutional investors. 43.7% of Precigen shares are held by insiders. Comparatively, 42.3% of Dyne … WebApr 3, 2024 · “ Dyne’s breakthrough approach brings the power of modern oligo therapeutics and other payloads to patients with serious muscle diseases," said Jason Rhodes, a partner at Atlas Venture and ...
WebDyne Therapeutics has 5 employees at their 1 location and $165 m in total funding,. See insights on Dyne Therapeutics including office locations, competitors, revenue, …
WebApr 9, 2024 · Dyne Therapeutics, Inc. Competitors. Emergent BioSolutions. NYSE:EBS US$529.5m. 4D Molecular Therapeutics. NasdaqGS:FDMT US$535.7m. Alector. NasdaqGS:ALEC US$518.1m. ARS Pharmaceuticals. NasdaqGM:SPRY US$549.4m. Price History & Performance. ... Dyne Therapeutics, Inc., a muscle disease company, … small cupcakes fayetteville gaWebApr 11, 2024 · Dyne Therapeutics has a 52-week low of $4.30 and a 52-week high of $15.63. Dyne Therapeutics ( NASDAQ:DYN - Get Rating ) last issued its quarterly earnings data on Thursday, March 2nd. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.10. sonaf in englishWebFeb 9, 2024 · Competitors: Unknown. Dyne Therapeutics Reviews ... Glassdoor gives you an inside look at what it's like to work at Dyne Therapeutics, including salaries, … son afflictionWebDyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary ... sona frameworkWebApr 7, 2024 · Summary Competitors Valuation Apr 7, 2024. ... Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is ... small cupcakes columbus ohioWebApr 4, 2024 · Dyne Therapeutics currently has a consensus target price of $25.83, suggesting a potential upside of 133.79%. Given Dyne Therapeutics’ higher possible upside, equities analysts plainly believe ... small cupcake papersWebFind real-time DYN - Dyne Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. DYN - Dyne Therapeutics Inc Stock quote - … small cupcake pan